Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS: Non-steroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal damage both in the upper and lower gastrointestinal tract. New anti-inflammatory drugs have been developed in an attempt to improve their gastrointestinal side effect profile. Our objective was to compare the effect on gastrointestinal permeability of acute equieffective doses of four different NSAIDs; three were designed to reduce gastrointestinal mucosal injury. MATERIALS: Healthy volunteers underwent sugar tests in a randomised fashion, 15 days apart, at: (1) baseline; (2) after two days of 75 mg slow release (microspheres) indomethacin; (3) after two days of 7.5 mg oral meloxicam which preferentially inhibits cyclooxygenase 2; and (4) after two days of 750 mg naproxen. A subgroup of subjects was tested after two days of 200 mg celecoxib. In each test, subjects ingested a solution containing sucrose, lactulose, and mannitol and sucralose, to evaluate gastroduodenal, intestinal, and colonic permeability, respectively. RESULTS: Gastric permeability was significantly affected by naproxen (p<0.05) but not by slow release indomethacin, meloxicam, or celecoxib. Intestinal permeability was significantly increased by the first three NSAIDs (p<0.05) but not by celecoxib. Abnormal lactulose/mannitol ratios were observed in 42% of meloxicam treatments, in 62% during indomethacin, and in 75% of subjects treated with naproxen. Finally, colonic permeability, as measured by sucralose, was not significantly increased by any of the four drugs. CONCLUSION: Our study provides evidence that the newly developed NSAIDs reduce gastric mucosal permeability significantly. However, most produced significant alteration of small intestinal permeability. In contrast, our results suggest that celecoxib seems to exhibit the most desirable gastrointestinal side effect profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Novel Oral Drug Formulations: Their Potential in Modulating Adverse Effects
Florence, A. T., & Jani, P. U. (1994) · Drug Safety · doi:10.2165/00002018-199410030-00005 · Cited by 84
Cited by
Human Intestinal Barrier Function in Health and Disease
König, J., Wells, J., Cani, P. D., García-Ródenas, C. L., MacDonald, T., Mercenier, A., Whyte, J., Troost, F., & Brummer, R.-J. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.54 · Cited by 780
Vanuytsel, T., van Wanrooy, S., Vanheel, H., Vanormelingen, C., Verschueren, S., Houben, E., Salim Rasoel, S., Tόth, J., Holvoet, L., Farré, R., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305690 · Cited by 615
Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage
Sostres, C., Gargallo, C. J., & Lanas, A. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4175 · Cited by 406
ZENG, J., LI, Y. ‐., ZUO, X. ‐., ZHEN, Y. ‐., YANG, J., & LIU, C. ‐. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03818.x · Cited by 189
LAINE, L., SMITH, R., MIN, K., CHEN, C., & DUBOIS, R. W. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03043.x · Cited by 189
Gastrointestinal safety pharmacology in drug discovery and development
Al-Saffar, A., da Costa, A. N., Delaunois, A., Leishman, D. J., Marks, L., Rosseels, M.-L., & Valentin, J.-P. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-46943-9_12 · Cited by 29
Metadata
- Authors
- Smecuol, E., Bai, J. C., Sugai, E., Vazquez, H., Niveloni, S., Pedreira, S., Mauriño, E., & Meddings, J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2001-11-01
- Volume
- 49
- Issue
- 5
- Pages
- 650-655
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2120662329
- Cited by
- 135
- References
- 2
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.